https://www.selleckchem.com/products/azd-5069.html
There were 88 fracture cases in the SGLT2is in combination with metformin therapy group and 79 in the control group. SGLT2is combined with metformin use did not influence fracture risk compared with metformin monotherapy or other comparators in patients with T2DM (OR = 0.97, 95% CI 0.71-1.32). After stratification by drug type, follow-up time, control regimen, and type of fracture, the upshots were still stable. SGLT2is and metformin combination therapy did not influence fracture risk compared with metformin monotherapy or other compar
Like
Comment
Share
